Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan

By sjmartinez • March 20, 2024

Heist RS, Sands J, Bardia A, Shimizu T, Lisberg A, Krop I, Yamamoto N, Kogawa T, Al-Hashimi S, Fung SSM, Galor A, Pisetzky F, Basak P, Lau C, Meric-Bernstam F. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev. 2024 Mar 11;125:102720. doi: 10.1016/j.ctrv.2024.102720. Epub ahead of print. PMID: 38502995.

Tags: Adverse events, Dato-DXd, Datopotamab deruxtecan, Hematology/Oncology, HR+/HER2− breast cancer, NSCLC, Publications, TNBC

Access to AlloTx for AML: the value of the social phenotype

Schiller G. Access to AlloTx for AML: the value of the social phenotype. Blood. 2025 Jun 19;145(25):2941-2942. doi: 10.1182/blood.2025028826. PMID: 40536784.

Life Expectancy of American Indian and Alaska Native Persons and Underreporting of Mortality in Vital Statistics

Bor J, Bird M, Hakes JK, Himmelstein DU, Himmelstein G, Woolhandler S. Life Expectancy of American Indian and Alaska Native Persons and Underreporting of Mortality[...]

Primary Cardiac Diffuse Large B-Cell Lymphoma Managed With Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report and Literature Review

Tai JW, Roufeh EN, Reed JP. Primary Cardiac Diffuse Large B-Cell Lymphoma Managed With Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report[...]